PCSK9 rs11591147 loss-of-function carriers have lower LDL cholesterol.

The claim that carriers of the PCSK9 rs11591147 loss-of-function (LoF) variant have lower LDL cholesterol, and that lacking this variant is consistent with a higher steady-state LDL particle burden, is strongly supported by clinical and mechanistic evidence. This genetic variant, also known as the R46L mutation, provides a "natural experiment" in lifetime lipid lowering.

Clinical evidence and effectiveness

The rs11591147 variant is a well-documented genetic protector against elevated LDL cholesterol (LDL-C). Large-scale meta-analyses and longitudinal studies consistently demonstrate that carriers of the minor T allele (the LoF variant) exhibit 10–25% lower LDL-C levels compared to non-carriers.

• Magnitude of effect: Clinical data show that the presence of the LoF variant reduces LDL-C by approximately 15–31 mg/dL. In contrast, non-carriers (those with the wild-type G allele) typically have LDL-C levels that are significantly higher—roughly 14.81 mg/dL higher per allele than their LoF counterparts.
• Cardiovascular protection: This lifelong reduction in LDL-C translates to a significant decrease in cardiovascular risk, with some cohorts showing up to an 88% reduction in major coronary events.

Mechanistic explanations

The mechanism for this protection involves the regulation of the LDL receptor (LDLR) on liver cells.

• Wild-type function: In those lacking the LoF variant, the PCSK9 protein binds to LDLRs on the surface of hepatocytes. This binding directs the receptors to lysosomes for degradation rather than allowing them to recycle back to the cell surface.
• Loss-of-function effect: The rs11591147 variant causes structural instability in the PCSK9 protein, weakening its binding to the LDLR.
• LDL clearance: With less PCSK9-mediated degradation, carriers of the variant have a higher density of LDLRs on their liver cells. This increased receptor availability allows the liver to clear LDL particles from the blood more efficiently, resulting in a lower steady-state LDL particle (LDL-P) burden.

Bottom line

The absence of the PCSK9 rs11591147 LoF variant leads to normal PCSK9 activity, which reduces the number of available LDL receptors and results in a higher steady-state LDL particle burden compared to those with the protective mutation.